Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Scaffolds from cancer - product for drug screening

Reference number
Coordinator Iscaff Pharma AB
Funding from Vinnova SEK 300 000
Project duration April 2021 - March 2022
Status Completed
Venture Innovative Startups
Call Innovative Startups step 1 spring 2021

Important results from the project

Iscaffpharma has a unique technology where the importance of the human microenvironment for the development of cancer can be used early in the pre-clinical development of drugs against cancer. We have been able to commercialize and reach out to paying customers. We have also developed synthetic scaffolds copying the human microenvironment. This offers a scalable product that can be used by pharmaceutical companies in pre-clinical analyzes. By offering our technology, we want to contribute to the development of new drugs and more effective treatment to be able to cure cancer.

Expected long term effects

Through the project, we have refined our service and made our technology available to research companies that develop new effective treatments for cancer. Our technology provides an early response to the expected effect of a treatment in humans. No other models today can offer this. By performing the analyzes in tumor tissue outside the patient, we can avoid risks with tests of treatments. Our model with synthetic scaffolds provides the opportunity to do drug screening on a larger scale in patient material. This also means that we can reduce the need for animal studies.

Approach and implementation

We have collaborated with the University of Gothenburg via contract research to offer pharmaceutical companies a unique pre-clinical evaluation of future treatments where you get an insight into the effects the drug actually has in humans. We have been able to refine how we work with the service offering and have been able to commercialize and reach out with our offer. Through development work at RISE, we have also been able to further develop our synthetic scaffolds to create a flexible model that can be adapted to different types of cancer.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 20 May 2022

Reference number 2021-00122